ReShape Lifesciences Inc.
RSLS
$2.90
$0.60526.42%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -42.75% | -8.93% | 6.36% | -12.82% | -15.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -42.75% | -8.93% | 6.36% | -12.82% | -15.00% |
| Cost of Revenue | -44.54% | 247.14% | -1.61% | -21.60% | -26.72% |
| Gross Profit | -41.55% | -28.39% | 11.72% | -5.03% | -4.82% |
| SG&A Expenses | -25.42% | -51.97% | -27.23% | -39.66% | -54.84% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -28.94% | -36.88% | -22.92% | -35.83% | -47.54% |
| Operating Income | 16.79% | 66.12% | 43.25% | 48.77% | 60.75% |
| Income Before Tax | 167.97% | -5.34% | 55.40% | 54.71% | 17.71% |
| Income Tax Expenses | -50.00% | -83.87% | 100.00% | 275.00% | 0.00% |
| Earnings from Continuing Operations | 167.21% | -3.71% | 55.26% | 54.34% | 17.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 167.21% | -3.71% | 55.26% | 54.34% | 17.62% |
| EBIT | 16.79% | 66.12% | 43.25% | 48.77% | 60.75% |
| EBITDA | 16.74% | 66.26% | 42.48% | 48.28% | 60.52% |
| EPS Basic | 114.02% | 61.41% | -- | -- | -- |
| Normalized Basic EPS | 113.95% | 61.61% | -- | -- | -- |
| EPS Diluted | 114.02% | 61.41% | -- | -- | -- |
| Normalized Diluted EPS | 113.95% | 61.61% | -- | -- | -- |
| Average Basic Shares Outstanding | 379.63% | 168.87% | -- | -- | -- |
| Average Diluted Shares Outstanding | 379.63% | 168.87% | -- | -- | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |